Watts Ryan J. 4
4 · Denali Therapeutics Inc. · Filed Oct 22, 2024
Insider Transaction Report
Form 4
Watts Ryan J.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2024-10-18$0.68/sh+40,000$27,200→ 275,807 total - Sale
Common Stock
2024-10-18$27.69/sh−40,000$1,107,600→ 235,807 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-18−40,000→ 1,078,091 totalExercise: $0.68Exp: 2025-08-20→ Common Stock (40,000 underlying)
Holdings
- 2,202,604(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 197,200 Unvested RSUs.
- [F2]The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.
- [F3]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $27.49 to $28.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- [F5]The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.